Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Seguridad y eficacia de NTX-001 en comparación con SOC en lesiones nerviosas periféricas únicas agudas

28 de octubre de 2026 actualizado por: Neuraptive Therapeutics Inc.

Estudio de fase 2a, multicéntrico, aleatorizado, cegado por el paciente y el evaluador, controlado, que evalúa la seguridad y la eficacia de NTX-001 en comparación con el SOC en el tratamiento de la lesión aguda de un nervio periférico seccionado que se produce por debajo del borde distal del plexo braquial y requiere reparación quirúrgica.

NTX-001 is a single use surgical product intended for use in conjunction with standard suture neurorrhaphy of severed nerves in patients between 16 and 80 years of age.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

NTX-001 (Product) is a surgical product that consists of an active solution (drug), an isolation chamber medical device (chamber or device) and two (2) other sterile solutions.

NTX-001 has been developed as a surgical product to be used in conjunction with standard suture neurorrhaphy of a severed nerve. Use of NTX-001 is intended to safely accelerate the often slow and diminished return of function in repaired nerves. It often takes months and/or years to determine if function will be restored. By that point, restoration is often incomplete and can result in lifelong motor and/or sensory deficits. By reconnecting (PEG-fusion) a substantial number of axons within a severed nerve, the degeneration-regeneration cycle and subsequent atrophy may be reduced or even prevented for those axons and their targets, respectively. NTX-001 (PEG-fusion) has the potential to avoid the consequences of protracted denervation of distal target tissues by eliminating the period of total denervation thus reducing the time to stable recovery and providing greater innervation to affected tissues.

Tipo de estudio

Intervencionista

Inscripción (Actual)

51

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Florida
      • Gainesville, Florida, Estados Unidos, 32607
        • UF Health - University of FL - Gainesville
      • Orlando, Florida, Estados Unidos, 32806
        • Orlando Health
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • University of Chicago
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46260
        • Indiana Hand to Shoulder Center
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21224
        • Johns Hopkins Bayview Medical Center
      • Baltimore, Maryland, Estados Unidos, 21218
        • Curtis National Hand Center
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Washington University
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43202
        • The Ohio State University Wexner Medical Center Hand and Upper Extremity Center
    • Virginia
      • Richmond, Virginia, Estados Unidos, 23398
        • Virginia Commonwealth University
    • Washington
      • Seattle, Washington, Estados Unidos, 98107
        • Harborview Medical Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

12 años a 80 años (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • The subject is at least 12 years of age and not older than 80.
  • The subject has sustained a confirmed (intra-op assessment) single transected peripheral nerve injury.
  • The subject's nerve injury is classified as Sunderland's Fourth and Fifth Degree (Class III)
  • The subject's nerve injury is amenable to minimal or acceptable tension, in direct, end-to-end repair.
  • The surgical repair will occur within 48 hours of injury.

Exclusion Criteria:

  • The subject has a PNI with a segmental loss (gap) that cannot be repaired with minimal or acceptable tension.
  • Other treatments known to affect the growth and/or physiology of the neural and vascular system.
  • The nerve injury has vascular damage that cannot be repaired to provide adequate perfusion of the injured site.
  • The subject is pregnant and/or is breastfeeding.
  • The subject has a significant medical comorbidity precluding immediate repair.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: NTX-001

NTX-001 used during surgical repair of an upper extremity peripheral nerve injury in conjuction with standard suture neurorrhaphy.

One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy. An isolation chamber medical device (device) is utilized to focus the application of PEG (Solution #2) on the coapted nerve for the required amount of exposure time.

Otros nombres:
  • Fusión de PEG
Sin intervención: Standard of Care

standard suture neurorrhaphy

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change From Baseline Michigan Hand Questionnaire Total Score (MHQ)
Periodo de tiempo: Baseline and Week 12

The MHQ measures hand function and is scored from 0-100; with 100 being the "best" score.

Baseline and Week 12

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Responder Analysis for % Recovery of MHQ Total Score > Than or = to 75% Cutoff
Periodo de tiempo: Baseline, Weeks 8, 12, 24, 48

The MHQ measures hand function and is scored from 0-100; with 100 being the "best" score.

Baseline, Weeks 8, 12, 24, 48
Change From Baseline Numeric Pain Rating Scale (NPRS)
Periodo de tiempo: Baseline and at Weeks 4, 8, 12, 24, 36 and 48

The NPRS measures pain intensity on a scale from 0 representing no pain and 10 to the worst pain as bad as you can imagine.

Baseline and at Weeks 4, 8, 12, 24, 36 and 48
Number of Responders to Modified British Medical Research Council (MMRC) Sensory Grading (S0-S4)
Periodo de tiempo: Baseline, Weeks 4, 8, 12, 24, 36 and 48

The MMRC sensory grading scale was used to assess sensory recovery based on pain/touch sensibility and static and moving two-point discrimination testing (STPD and MTPD). The scale ranges from S0 to S4, where S0 = no sensory recovery; S1 = recovery of deep cutaneous pain sensibility; S2 = recovery of some superficial pain and tactile sensibility; S3 = recovery of pain and tactile sensibility with imperfect localization and two-point discrimination; and S4 = complete sensory recovery. Higher scores indicate better sensory recovery. A responder was defined as a participant achieving a sensory recovery grade of S3 or greater (S3+). Data presented are the percentage of participants who met the S3+ responder criterion at each assessment time point.

Baseline, Weeks 4, 8, 12, 24, 36 and 48
Number of Responders to Modified British Medical Research Council (MMRC) Motor Grading (M0-M5)
Periodo de tiempo: Baseline, Weeks 4, 8, 12, 24, 36 and 48

The MMRC motor grading scale was used to assess motor recovery. Motor function was evaluated on an ordinal scale ranging from M0 to M5, where M0 indicates no muscle contraction and M5 indicates normal muscle strength. Grades were defined as follows: M0 = no contraction; M1 = muscle contraction without joint movement; M2 = active movement with gravity eliminated; M3 = active movement against gravity; M4 = active movement against resistance; and M5 = normal muscle strength. Higher scores indicate better motor recovery. A responder was defined as a participant achieving a motor function score of M3 or greater (M3+). Data presented are the percentage of participants meeting the M3+ responder criterion at each assessment time point.

Baseline, Weeks 4, 8, 12, 24, 36 and 48
Number of Responders to Semmes-Weinstein Monofilament Test (SWMT)
Periodo de tiempo: Baseline, Weeks 4, 8, 12, 24, 36 and 48

The Semmes-Weinstein Monofilament Test (SWMT) was used to assess sensory function of the affected nerve. A responder was defined as a participant with a return to normal gauge sensation (2.83 g) for the affected nerve. Lower scores indicate better sensory function, with 2.83 g corresponding to normal sensation. Data presented are the percentage of participants who met the responder criterion at each assessment time point.

Baseline, Weeks 4, 8, 12, 24, 36 and 48
Change From Baseline Cold Intolerance Symptom Severity (CISS)
Periodo de tiempo: Baseline and at Weeks 4, 8, 12, 24 and 48

The CISS focuses on the impact of cold intolerance on activities of daily life; the score ranges a score between 0 and 100, where 0 is no symptoms at all and 100 is the most severe symptoms you can possibly imagine.

Baseline and at Weeks 4, 8, 12, 24 and 48
Number of Responders to Patient Global Impression of Change (PGIC)
Periodo de tiempo: Baseline, Weeks 4, 8, 12, 24 and 48

The Patient Global Impression of Change (PGIC) is a patient-reported assessment of overall change in health status since treatment initiation. Participants rate their condition on a 7-point scale: 1 = very much worse, 2 = much worse, 3 = minimally worse, 4 = no change, 5 = minimally improved, 6 = much improved, and 7 = very much improved. Higher scores indicate greater perceived improvement. A responder was defined as a participant with a PGIC score of 5 or greater. Data presented are the percentage of participants who met the responder criterion at each assessment time point.

Baseline, Weeks 4, 8, 12, 24 and 48

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Change From Baseline in Michigan Hand Questionnaire (MHQ) Activities of Daily Living
Periodo de tiempo: Baseline and at Weeks 8, 12, 24, 48

The MHQ Two Domain Score analyses consisted of the average of the domain Activities of Daily Living (ADL). MHQ Activities of Daily Living normalized score ranges from 0 to 100, with 0 being the worst score and 100 the best.

Baseline and at Weeks 8, 12, 24, 48
Change From Baseline in MHQ Pain Score
Periodo de tiempo: Baseline and at Weeks 8, 12, 24, 48

The MHQ Two Domain Score analyses consisted of the average of the pain domain. MHQ Pain normalized score ranges from 0 to 100, with 0 being the best score and 100 the worst.

Baseline and at Weeks 8, 12, 24, 48

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Silla de estudio: Seth Schulman, MD, Neuraptive Therapeutics Inc.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

25 de septiembre de 2020

Finalización primaria (Actual)

27 de junio de 2024

Finalización del estudio (Actual)

27 de junio de 2024

Fechas de registro del estudio

Enviado por primera vez

10 de septiembre de 2020

Primero enviado que cumplió con los criterios de control de calidad

29 de septiembre de 2020

Publicado por primera vez (Actual)

1 de octubre de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

28 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir